Journal Article

Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial

Torrisi, Rosalba, Cabula, Roberta, Barbieri, Erika, Dozin, Beatrice, Pezzella, Modestino, Errico, Valentina, Rubino, Luca, Fernandes, Bethania, Meneghini, Graziano, Cabula, Carlo, Mirandola, Sara, Friedman, Daniele, Michieletto, Silvia, Pollini, Giovanni, Franceschini, Davide, Chiappa, Corrado, Ghilli, Matteo, Sagona, Andrea, Tinterri, Corrado, Bruzzi, Paolo, Sibilio, Andrea, Bounous, Valentina, Bottini, Alberto, Caruso, Francesco, Cariello, Anna, Battaglia, Claudio, Taffurelli, Mario, Falco, Giuseppe, Di Bartolo, Francesco, Magni, Carla, Ciuffreda, Luigi, Rovera, Francesca Angela, Scorsetti, Marta, Grossi, Simona, Biglia, Nicoletta, Lazzaretti, Maria Grazia, Roncella, Manuela, Troilo, Vito Leopoldo, Tazzioli, Giovanni, Castiglione, Gaetano, Custodero, Olindo, Curcio, Annalisa, Marrazzo, Emilia, Testori, Alberto, Rossi, Camilla, tunato, Lucio, Boni, Luca, Tavoletta, Maria Saveria, Coiro, Saverio, Bettini, Rossella, Santoro, Armando, Canavese, Giuseppe, Cucchi, Maria Cristina, Murgo, Roberto, Chifu, Camelia, Meli, Emanuele Zarba, Gatzemeier, Wolfgang, Saibene, Tania, Spoto, Ruggero, Dani, Carla, Gentile,

2022

Overview

BackgroundThe SINODAR-ONE trial is a prospective noninferiority multicenter randomized study aimed at assessing the role of axillary lymph node dissection (ALND) in patients undergoing either breast-conserving surgery or mastectomy for T1–2 breast cancer (BC) and presenting one or two macrometastatic sentinel lymph nodes (SLNs). The endpoints were to evaluate whether SLN biopsy (SLNB) only was associated with worsening of the prognosis compared with ALND in terms of overall survival (OS) and relapse.MethodsPatients were randomly assigned (1:1 ratio) to either removal of ≥ 10 axillary level I/II non-SLNs followed by adjuvant therapy (standard arm) or no further axillary treatment (experimental arm).ResultsThe trial started in April 2015 and ceased in April 2020, involving 889 patients. Median follow-up was 34.0 months. There were eight deaths (ALND, 4; SNLB only, 4), with 5-year cumulative mortality of 5.8% and 2.1% in the standard and experimental arm, respectively (p = 0.984). There were 26 recurrences (ALND 11; SNLB only, 15), with 5-year cumulative incidence of recurrence of 6.9% and 3.3% in the standard and experimental arm, respectively (p = 0.444). Only one axillary lymph node recurrence was observed in each arm. The 5-year OS rates were 98.9% and 98.8%, in the ALND and SNLB-only arm, respectively (p = 0.936).ConclusionsThe 3-year survival and relapse rates of T1–2 BC patients with one or two macrometastatic SLNs treated with SLNB only, and adjuvant therapy, were not inferior to those of patients treated with ALND. These results do not support the use of routine ALND.

• Publisher: Springer Nature B.V
• Subject: Biopsy / Breast cancer / Lymph nodes / Lymphatic system / Medical prognosis / Metastases / Patients / Survival